18F-FDG-PET and PET/CT for evaluating primary bone tumors

Erik Mittra, Andrei Iagaru

Research output: Contribution to journalArticle

Abstract

Imaging is critical for the proper evaluation of patients with primary tumors of bone. There is a growing role for 18F-fluorodeoxyglucose PET and PET/computed tomography (CT) in the grading, staging, prognostication, evaluation of therapeutic response, and detection of recurrent disease in bone. These modalities can also be used to help differentiate benign from malignant disorders of bone.

Original languageEnglish (US)
Pages (from-to)327-339
Number of pages13
JournalPET Clinics
Volume5
Issue number3
DOIs
StatePublished - Jul 2010

Keywords

  • Benign
  • Fluorodeoxyglucose
  • Malignant
  • Multiple myeloma
  • Positron emission tomography
  • Sarcoma

ASJC Scopus subject areas

  • Radiation
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of '<sup>18</sup>F-FDG-PET and PET/CT for evaluating primary bone tumors'. Together they form a unique fingerprint.

  • Cite this